BioSpace News Archive

Coherus BioSciences, Inc., announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the common stock of the Company to five newly hired employees with a per share exercise price of $1.94, the closing trading price on the grant date.

Standard BioTools Inc. announced that leading independent proxy advisory firm Institutional Shareholder Services has recommended that Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic at the Company’s upcoming Special Meeting of Stockholders to be held on January 4, 2024.

RaySearch Laboratories AB announces the launch of RayStation®* 2024A, the latest version of the company’s comprehensive treatment planning system.

Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that its founder and executive chairman, Jeff Arnold, and incoming chief executive officer, Brent Layton, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 10, 2024 at 8:15 a.m. PST.

Outlook Therapeutics, Inc., a biopharmaceutical company working to achieve U.S. Food and Drug Administration approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, announced recent corporate highlights and financial results for its fiscal year ended September 30, 2023.

Seelos Therapeutics, Inc. released a letter to its stockholders from Raj Mehra, Ph.D., Chairman and Chief Executive Officer of Seelos, the text of which is copied below.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has received approval from the Alfred Human Research Ethics Committee (HREC) to conduct a Phase 1 clinical trial of drug candidate OLX75016 (the candidate of OLX702A) for the treatment of non-alcohol steatohepatitis (NASH).

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) today announced submission of an efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS (delandistrogene moxeparvovec-rokl) to expand its labeled indication as follows “[ELEVIDYS is indicated for] the treatment of Duchenne muscular dystrophy (DMD) patients with a confirmed mutation in the DMD gene.”

Centene Corporation (NYSE: CNC) announced today it will present at the 42nd Annual J. P. Morgan Healthcare Conference, to be held Monday, January 8 – Thursday, January 11, 2024, in San Francisco.

TC BioPharm today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares.